Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lauren L. Atwell is active.

Publication


Featured researches published by Lauren L. Atwell.


Molecular Nutrition & Food Research | 2015

Absorption and chemopreventive targets of sulforaphane in humans following consumption of broccoli sprouts or a myrosinase-treated broccoli sprout extract

Lauren L. Atwell; Anna Hsu; Carmen P. Wong; Jan F. Stevens; Deborah Bella; Tian-Wei Yu; Clifford B. Pereira; Christiane V. Löhr; John M. Christensen; Roderick H. Dashwood; David E. Williams; Jackilen Shannon; Emily Ho

SCOPE Sulforaphane (SFN), an isothiocyanate derived from crucifers, has numerous health benefits. SFN bioavailability from dietary sources is a critical determinant of its efficacy in humans. A key factor in SFN absorption is the release of SFN from its glucosinolate precursor, glucoraphanin, by myrosinase. Dietary supplements are used in clinical trials to deliver consistent SFN doses, but myrosinase is often inactivated in available supplements. We evaluated SFN absorption from a myrosinase-treated broccoli sprout extract (BSE) and are the first to report effects of twice daily, oral dosing on SFN exposure in healthy adults. METHODS AND RESULTS Subjects consumed fresh broccoli sprouts or the BSE, each providing 200 μmol SFN daily, as a single dose and as two 100-μmol doses taken 12 h apart. Using HPLC-MS/MS, we detected ∼3 x higher SFN metabolite levels in plasma and urine of sprout consumers, indicating enhanced SFN absorption from sprouts. Twelve-hour dosing retained higher plasma SFN metabolite levels at later time points than 24-hour dosing. No dose responses were observed for molecular targets of SFN (i.e. heme oxygenase-1, histone deacetylase activity, p21). CONCLUSION We conclude that the dietary form and dosing schedule of SFN may impact SFN absorption and efficacy in human trials.


Current Pharmacology Reports | 2015

Epigenetic Regulation by Sulforaphane: Opportunities for Breast and Prostate Cancer Chemoprevention

Lauren L. Atwell; Laura M. Beaver; Jackilen Shannon; David E. Williams; Roderick H. Dashwood; Emily Ho

Sulforaphane (SFN) is a phytochemical derived from cruciferous vegetables that has multiple molecular targets and anti-cancer properties. Researchers have demonstrated several chemopreventive benefits of SFN consumption, such as reductions in tumor growth, increases in cancer cell apoptosis, and disruption of signaling within tumor microenvironments both in vitro and in vivo. Emerging evidence indicates that SFN exerts several of its chemopreventive effects by altering epigenetic mechanisms. This review summarizes evidence of the impact of SFN on epigenetic events and how they relate to the chemopreventive effects of SFN observed in preclinical and clinical studies of breast and prostate cancers. Specific areas of focus include the role of SFN in the regulation of cell cycle, apoptosis, inflammation, antioxidant defense, and cancer cell signaling and their relationships to epigenetic mechanisms. Finally, remaining challenges and research needs for translating mechanistic work with SFN into human studies and clinical intervention trials are discussed.


Cancer Prevention Research | 2015

Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy

Lauren L. Atwell; Zhenzhen Zhang; Motomi Mori; Paige E. Farris; John T. Vetto; Arpana Naik; Karen Y. Oh; Philippe Thuillier; Emily Ho; Jackilen Shannon

Epidemiologic studies suggest a protective effect of cruciferous vegetables on breast cancer. Sulforaphane (SFN), an active food component derived from crucifers, has been shown to be effective in breast cancer chemoprevention. This study evaluated the chemopreventive effect of SFN on selective biomarkers from blood and breast tissues. In a 2- to 8-week double-blinded, randomized controlled trial, 54 women with abnormal mammograms and scheduled for breast biopsy were randomized to consume a placebo or a glucoraphanin (GFN) supplement providing SFN (n = 27). Plasma and urinary SFN metabolites, peripheral blood mononuclear cell (PBMC) histone deacetylase (HDAC) activity, and tissue biomarkers (H3K18ac, H3K9ac, HDAC3, HDAC6, Ki-67, p21) were measured before and after the intervention in benign, ductal carcinoma in situ, or invasive ductal carcinoma breast tissues. Within the supplement group, Ki-67 (P = 0.003) and HDAC3 (P = 0.044) levels significantly decreased in benign tissue. Pre-to-postintervention changes in these biomarkers were not significantly different between treatment groups after multiple comparison adjustment. GFN supplementation was associated with a significant decrease in PBMC HDAC activity (P = 0.04). No significant associations were observed between SFN and examined tissue biomarkers when comparing treatment groups. This study provides evidence that GFN supplementation for a few weeks is safe but may not be sufficient for producing changes in breast tissue tumor biomarkers. Future studies employing larger sample sizes should evaluate alternative dosing and duration regimens to inform dietary SFN strategies in breast cancer chemoprevention. Cancer Prev Res; 8(12); 1184–91. ©2015 AACR.


Toxicology and Applied Pharmacology | 2013

Differential modulation of dibenzo[def,p]chrysene transplacental carcinogenesis: Maternal diets rich in indole-3-carbinol versus sulforaphane

Lyndsey E. Shorey; Erin P. Madeen; Lauren L. Atwell; Emily Ho; Christiane V. Löhr; Clifford B. Pereira; Roderick H. Dashwood; David E. Williams

Cruciferous vegetable components have been documented to exhibit anticancer properties. Targets of action span multiple mechanisms deregulated during cancer progression, ranging from altered carcinogen metabolism to the restoration of epigenetic machinery. Furthermore, the developing fetus is highly susceptible to changes in nutritional status and to environmental toxicants. Thus, we have exploited a mouse model of transplacental carcinogenesis to assess the impact of maternal dietary supplementation on cancer risk in offspring. In this study, transplacental and lactational exposure to a maternal dose of 15mg/Kg B.W. of dibenzo[def,p]chrysene (DBC) resulted in significant morbidity of offspring due to an aggressive T-cell lymphoblastic lymphoma. As in previous studies, indole-3-carbinol (I3C, feed to the dam at 100, 500 or 1000ppm), derived from cruciferous vegetables, dose-dependently reduced lung tumor multiplicity and also increased offspring survival. Brussels sprout and broccoli sprout powders, selected for their relative abundance of I3C and the bioactive component sulforaphane (SFN), respectively, surprisingly enhanced DBC-induced morbidity and tumorigenesis when incorporated into the maternal diet at 10% wt/wt. Purified SFN, incorporated in the maternal diet at 400ppm, also decreased the latency of DBC-dependent morbidity. Interestingly, I3C abrogated the effect of SFN when the two purified compounds were administered in equimolar combination (500ppm I3C and 600ppm SFN). SFN metabolites measured in the plasma of neonates positively correlated with exposure levels via the maternal diet but not with offspring mortality. These findings provide justification for further study of the safety and bioactivity of cruciferous vegetable phytochemicals at supplemental concentrations during the perinatal period.


Public Health Nutrition | 2016

Associations between cruciferous vegetable intake and selected biomarkers among women scheduled for breast biopsies

Zhenzhen Zhang; Lauren L. Atwell; Paige E. Farris; Emily Ho; Jackilen Shannon

OBJECTIVE To examine the relationship between dietary cruciferous vegetable intake and selected tumour biomarkers for histone acetylation (H3K9ac, H3K18ac, HDAC3 and HDAC6), proliferation (Ki-67) and cell-cycle regulation (p21) from breast tissue. DESIGN The study used baseline data of women recruited to participate in a clinical trial of sulforaphane supplement. Dietary cruciferous vegetable intake was collected through a validated Arizona Cruciferous Vegetable Intake Questionnaire. Breast tissue was obtained from biopsy samples. Spearman correlations were calculated between intake of specific cruciferous vegetables and biomarkers. Tissue biomarkers were log2-transformed to obtain approximate normality. Linear regression analyses were conducted to examine associations between cruciferous vegetable intake and biomarkers adjusting for age and use of non-steroidal anti-inflammatory drugs. False discovery rate (FDR) was used to account for multiple comparisons. SETTING Clinical trial baseline. SUBJECTS Fifty-four women who had abnormal mammogram findings and were scheduled for breast biopsy. RESULTS Mean intake of total cruciferous vegetables from all food sources was 81·7 (sd 57·3) g/d. Mean urinary total sulforaphane metabolites was 0·08 (sd 0·07) µm/mm creatinine. Total cruciferous vegetable intake was inversely associated with Ki-67 protein expression in breast ductal carcinoma in situ (DCIS) tissue (β=-0·004; se=0·001; FDR q value=0·03), but not in benign or invasive ductal carcinoma (IDC) tissue. No association was found for other biomarkers measured (HDAC3, HDAC6, H3K9, H3K18 and p21) in all tissues examined (benign, DCIS and IDC). CONCLUSIONS The present study sought to provide additional evidence for the potential role of sulforaphane in histone acetylation and cell proliferation. Here, we report that total cruciferous vegetable intake is associated with decreased cell proliferation in breast DCIS tissue.


The FASEB Journal | 2016

Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy

Lauren L. Atwell; Zhenzhen Zhang; Motomi Mori; Paige E. Farris; John T. Vetto; Arpana Naik; Karen Y. Oh; Philippe Thuillier; Emily Ho; Jackilen Shannon


The FASEB Journal | 2015

Plasma Metabolomic Profiles in Healthy Adults following Consumption of Broccoli Sprouts

Lauren L. Atwell; John D. Clarke; Anna Hsu; Deborah Bella; Jaewoo Choi; Jan F. Stevens; Cliff Pereira; Yuan Jiang; Roderick H. Dashwood; David E. Williams; Emily Ho


The FASEB Journal | 2014

Bioavailability and metabolomic targets of sulforaphane in humans (1036.2)

Lauren L. Atwell; John D. Clarke; Anna Hsu; Deborah Bella; Jan F. Stevens; Roderick H. Dashwood; David E. Williams; Emily Ho


Archive | 2014

Plasma metabolites altered by sulforaphane in humans

Kimberly J. Kelsey; Lauren L. Atwell; John D. Clarke; Anna Hsu; Deborah Bella; Jan F. Stevens; Roderick H. Dashwood; David E. Williams; Emily Ho


The FASEB Journal | 2013

Sulforaphane bioavailability and bioactivity in humans

Lauren L. Atwell; John D. Clarke; Anna Hsu; Deborah Bella; Jan F. Stevens; Roderick H. Dashwood; David E. Williams; Emily Ho

Collaboration


Dive into the Lauren L. Atwell's collaboration.

Top Co-Authors

Avatar

Emily Ho

Oregon State University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anna Hsu

Oregon State University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge